We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation | Adolescent and Young Adult Health

Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females

Annika M. Hofstetter, MD, PhD, MPH1,2,3; Danielle C. Ompad, PhD4,5; Melissa S. Stockwell, MD, MPH1,6,7; Susan L. Rosenthal, PhD1,6,8; Karen Soren, MD1,6,7
[+] Author Affiliations
1Department of Pediatrics, Columbia University, New York, New York
2Department of Pediatrics, University of Washington, Seattle
3Seattle Children’s Research Institute, Seattle, Washington
4College of Global Public Health, New York University, New York
5Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
6New York–Presbyterian Hospital, New York
7Department of Population and Family Health, Mailman School of Public Health, Columbia University, New York, New York
8Department of Psychiatry, Columbia University, New York, New York
JAMA Pediatr. 2016;170(5):445-452. doi:10.1001/jamapediatrics.2015.3926.
Text Size: A A A
Published online

Importance  The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9- through 26-year-old females in 2006. Postlicensure studies in Australia, Denmark, and Canada have demonstrated vaccine effectiveness against abnormal cervical cytology results. However, there are limited data describing postlicensure effectiveness in the United States, particularly among minority females at higher risk for HPV infection and cervical cancer.

Objective  To examine the effect of HPV vaccination on abnormal cervical cytology results among minority females.

Design, Setting, and Participants  Retrospective cohort study conducted between January 2007 and January 2014 at 16 academically affiliated community clinics serving a low-income minority population. Included in this study was a population-based sample of 16 266 females aged 11 through 20 years as of January 1, 2007, who received care at a participating clinic on or after that date.

Exposure  Human papillomavirus vaccination, stratified by the number of doses.

Main Outcomes and Measures  Cervical cytology abnormality following either HPV vaccination or, if unvaccinated, the first missed opportunity for HPV vaccination after January 1, 2007. Abnormalities were defined as atypical glandular cells, atypical squamous cells of undetermined significance, atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion, low-grade squamous intraepithelial lesions, or high-grade squamous intraepithelial lesions.

Results  There were 4127 female patients who initiated quadrivalent HPV vaccination or had their first missed HPV vaccination opportunity from 11 through 20 years of age and underwent subsequent cervical cytology screening. The patients were primarily Spanish speaking (n = 2297; 58.3%) and publicly insured (n = 3801; 92.1%). The detection rate for an abnormal cervical cytology result during the observation period was lower among vaccinated (≥1 dose) (79.1 per 1000 person-years) vs unvaccinated (125.7 per 1000 person-years) females. The risk for an abnormal cervical cytology result was lower among vaccinated vs unvaccinated females (hazard ratio [HR], 0.64; 95% CI, 0.57-0.73), particularly if the 3-dose series was completed (HR, 0.48; 95% CI, 0.41-0.56) or if the vaccine was administered from 11 through 14 years of age (≥1 dose: HR, 0.36; 95% CI, 0.16-0.79; 3 doses: HR, 0.27; 95% CI, 0.12-0.63). This protective effect remained after adjusting for demographics, clinic type, abnormal baseline cervical cytology result, and baseline Chlamydia screening (as proxy for sexual experience).

Conclusions and Relevance  This study demonstrated the HPV vaccine is effective in a real-world setting of high-risk patients with variable HPV vaccination patterns.

Figures in this Article


Place holder to copy figure label and caption
Figure 1.
Schematic of Study Population

aA total of 3013 neither initiated human papillomavirus (HPV) vaccination nor had a missed opportunity for HPV vaccination from 11 through 20 years of age.

bScreened following initiation of HPV vaccination or, if unvaccinated, the first missed opportunity for HPV vaccination after January 1, 2007.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Time to Cervical Cytology Abnormality Among Fully Vaccinated (3 Doses) and Unvaccinated Participants

Time (years) to the first abnormal cervical cytology result after either initiation of HPV vaccination or the first missed vaccination opportunity, if unvaccinated, in the entire study population (n = 2828) (A) and among those aged 11 through 14 years (n = 124) (B).

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed